Once upon a time, the 'space race' meant the grand strategic competition between the USA and the USSR to gain control of the heavens. The superpowers designed and built satellites, manned capsules, orbital **** ecraft and long-endurance **** e stations, and NASA even sent the Apollo landers to put men on the Moon.
Today, the **** e race is heating up again, but in a very different way. Yes, the governments are still involved – NASA's Artemis program is targeting the Moon, the Russians have a Soyuz escape ship docked at the International **** e Station, and other powers such as the EU, China, and India have large-scale **** e programs. But the real difference – and a lot of the innovation – is coming from commercial players working alongside government **** e agencies.
This past summer, Elon Musk's **** eX went public, in Wall Street's largest ever IPO. The company is pioneering reusable large rockets, and has already made history with privately launched and/or publicly funded missions of the Falcon 9 rocket and Crew Dragon capsule.
Promotion
55% Off TipRanks

#once

Saudi Arabia suspends Yanbu oil loadings after halting its East-West pipeline, sending Brent back to $108.
Asia's Oil Crunch Sends Regional Benchmarks to Record Highs
- Asia's oil industry is facing a double whammy of supply shortages and better-than-expected demand, with crude differentials across the region gradually climbing towards record highs.
- Futures prices on China's Shanghai Futures Exchange rose to $138 per barrel on Tuesday, the highest reading on record, as Chinese refiners scramble to put their hands on available October supply.
- Saudi Aramco's announced halt in Yanbu loadings could see some recovery in exports from Saudi terminals in the Gulf, however these flows would be massively constrained by unprecedented freight rates.

#record #highs #supply #west

On September 11, Dell Technologies Inc. (NYSE:DELL) shares jumped more than 11% after RBC Capital Markets initiated coverage of the company with an Outperform rating and a price target of $640.
The latest rally adds to an already strong year for Dell Technologies Inc. (NYSE:DELL), with the stock having gained over 300% so far in 2026. The company has become one of the biggest vendors for Nvidia-based servers and related equipment, benefiting from strong demand for AI infrastructure from cloud companies and enterprises.
Photo by Pok Rie on Pexels
RBC ***** yst David Paige wrote in a note that Dell Technologies Inc. (NYSE:DELL) is showing no signs of slowing. RBC believes that the company "continues to be well positioned to benefit from a multi-year AI infrastructure spending cycle."
Paige pointed out that "Dell Technologies Inc.'s (NYSE:DELL) best-in-class supply chain represents a competitive moat that differentiates the company during periods of supply disruption, as customers increasingly turn to Dell Technologies Inc. (NYSE:DELL) for a 'calming hand' during periods of supply volatility/constraints."

#paige

Interested in Netflix, Inc.? Here are five stocks we like better.
Netflix received 25 negative revisions in 90 days, yet 54 **** ysts remain bullish, seeing over 20% upside despite reduced price targets.
Meta Platforms faces 21 downgrades tied to rising CapEx and weak Q2 results, but **** ysts still rate it a Moderate Buy with about 20% upside.
Lululemon's downgrades reflect genuine fundamental deterioration, with 29 **** ysts giving it a consensus Reduce rating and mostly Hold or Sell ratings.
Downgrades rarely help bullish traders, hurting sentiment and price action—unless, of course, you're looking for a good stock to buy into. As always, it's the trend that matters, because a downgrade or price target reduction can mean different things in different situations.

#bullish #upside #interested #here

Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.

#vaccine #pfizer #NYSE

Meta (META) on Tuesday officially unveiled its Meta One subscription service as part of the company's effort to further monetize its enormous AI spending and diversify its revenue stream.
The plans, which start at $2.99 per month for single-product plans, $7.99 for individual bundles, and $14.99 for creator and business bundles, provide a number of features for users looking to get more out of their Instagram, Facebook, and WhatsApp accounts.
Instagram Plus and Facebook Plus allow users to keep their stories up for 48 hours instead of 24, send animated super reactions and super hearts to stories, preview stories without showing up as a viewer in other users' lists, and more.
WhatsApp Plus lets you share exclusive stickers, get exclusive ringtones for contacts, and pin up to 20 different chats.

#meta #users #Instagram #plans

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.

#stage #survival

The dollar index (DXY00) is up +0.11% today and is just below Monday's 1.5-week high. Today's +1% rise in WTI crude oil prices raises inflation expectations and could persuade the Fed to tighten monetary policy, which supports the dollar. Also, today's increase in the 10-year T-note yield to a 19-year high of 5.04% strengthens the dollar's interest rate differentials. In addition, expectations that the Fed will raise interest rates by 25 bp at the Tue/Wed FOMC meeting support the dollar. The dollar fell from its best level today after the Sep Empire manufacturing survey came in weaker than expected.
The US Sep Empire manufacturing survey of general business conditions fell -13.0 points to 7.6, weaker than expectations of 15.0.
Dollar Edges Higher as Stocks Fall and Crude Oil Rallies
Dollar Rises on Surging Crude Prices and T-Note Yields
Dollar Climbs as Stocks Sink and Crude Oil Surges

#empire #stocks #note #year

Goleta, California-based Deckers Outdoor Corporation (DECK) is a global footwear and lifestyle company with products spanning performance running, outdoor activities, and premium casual fashion. Valued at a market cap of $11.1 billion, the company offers its products under the UGG, HOKA, Teva, Koolaburra, and AHNU brand names.
Companies with a market cap between $10 billion and $200 billion are typically called "large-cap stocks," and DECK fits that definition. Its portfolio of distinctive, high-growth footwear brands, particularly HOKA and UGG, drives its market dominance. HOKA stands out for its performance-driven, comfort-focused running shoes, while UGG combines its iconic heritage with evolving lifestyle products. This strong brand equity, differentiated product design, and loyal customer base give Deckers pricing power and help it compete beyond traditional footwear trends.
Goldman Sachs Expects Fed Chair Kevin Warsh to Raise Rates This Week — But Not Because of Oil Prices.
Morgan Stanley Doubles Down on Apple Stock as New Offerings Become 'More Exciting'
The EV Bubble Has Burst. How to Play Rivian Stock Now.

#billion

Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.

#disease

Investors choosing between Carnival (NYSE:CCL) and Uber Technologies (NYSE:UBER) must decide between a capital-intensive cruise leader and a high-growth technology platform. Both companies have shown resilience, but their financial structures offer very different risks.
Carnival operates as a global giant in the travel industry, managing a diverse fleet of ships that cater to millions of vacationers. Uber dominates the gig economy by connecting riders, diners, and shippers with service providers through its proprietary mobile applications and digital infrastructure.
As a major player among consumer discretionary stocks, Carnival operates a massive fleet of over 90 ships across eight distinct brands. In its latest annual report, the company highlighted a workforce of over 160,000 team members who served approximately 13.5 million guests throughout 2025. This scale allows the company to source passengers from major global markets, and notably, no single travel agency group accounted for more than 10% of total revenue during the year.
In FY 2025, revenue reached nearly $26.6 billion, representing a growth rate of roughly 6.4% compared to the prior year. This top-line expansion helped the company generate a net income of approximately $2.8 billion, a significant improvement over the $1.9 billion recorded in 2024. The net margin improved to 10.4%, indicating that the company is successfully converting a larger portion of its sales into actual profit.
Based on its November 2025 balance sheet, Carnival carries a debt-to-equity ratio of 2.3x, which is the total debt divided by shareholder equity. Its current ratio, a measure of current **** ets relative to current liabilities, is nearly 0.3x, suggesting tight short-term liquidity. However, the company generated close to $2.6 billion in free cash flow, which is cash from operations minus capital expenditures, providing capital for debt reduction and fleet maintenance.

#carnival #fleet #current

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.

#biontech #survival

Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Revenue growth of 60% year-over-year was driven by a combination of competitive share gains, market expansion, and a higher mix of in-network patients.
Management attributes the 11th consecutive quarter of gross margin expansion to attractive unit economics and volume leverage inherent in the rental business model.
The 'integrated care model' is cited as a key differentiator, where therapeutic protection is paired with responsive support services to convert clinical insights into urgent patient care.
Strategic territory management, including splitting high-volume 'platinum' territories and adding clinical specialists, is compounding growth by deepening penetration in existing accounts.

#Growth #tell

VICTORIA, SEYCHELLES, September 16th, 2026, Chainwire
Bitget has published its August 2026 Proof of Reserves report, marking the 45th consecutive monthly disclosure since the program began in December 2022, with a total reserve ratio of 122% for the month. Separately, Bitget's August 2026 Protection Fund valuation report recorded an average monthly value of $382 million, backed by 5,500 BTC held as a separate protection reserve.
Bitget publishes both monthly Proof of Reserves and monthly Protection Fund valuation reports — two separate disclosures providing visibility into different parts of the platform's ***** et-protection framework. The August PoR reserve ratio of 122% means Bitget's reported reserves for tracked ***** ets exceeded the corresponding user balances included in the snapshot. A full per-asset breakdown is available on Bitget's Proof of Reserves page.
A reserve ratio above 100% reflects the position captured in a particular reporting snapshot and should not be interpreted as a financial audit or a guarantee of future solvency.
The Protection Fund's August valuation ranged from approximately $345.3 million on Aug 1, 2026 to $441.5 million on Aug 27, 2026, with an average monthly valuation of $382 million. Its dollar value fluctuates with Bitcoin's market price because the fund is backed by 5,500 BTC. Bitget established the fund in 2022 with an initial $300 million commitment, and its valuation remained above that level throughout August.

#valuation

WASHINGTON (AP) — The United States has confirmed for the first time that it has deployed weapons in ******* e, a remarkable revelation after previous warnings about countries such as Russia possibly weaponizing a global frontier long agreed in treaties to be used for only peaceful purposes.
Air Force Secretary Troy Meink said Monday that the U.S. has fielded "on-orbit ******* e control weapons capable of defending the Joint Force against hostile adversary action."
Meink did not detail what the weapons were, how they work or if they were targeting other objects in ******* e or on Earth. The U.S. had warned two years ago that Russia was developing a new ******* e-based, anti-satellite weapon, though the White House said the danger wasn't imminent at the time.
But reports of the anti-satellite weapon reflected longstanding worries about ******* e threats from Russia and China, given that much U.S. infrastructure is dependent on satellite communications. The U.S. has also previously demonstrated its own abilities to shoot down satellites from Earth.
In his remarks to the Air and ******* e Forces ******* ociation's Air, ******* e & Cyber Conference, Meink also said the Air Force was adding more autonomous systems to its capabilities and predicted the service would look "radically different" by 2032. For example, he foresaw one-way attack drones replacing artillery as the "primary killer."

#space #earth

On September 14, Radiant Logistics (NYSEAMERICAN:RLGT) held its fourth fiscal quarter earnings call, and the headline numbers landed harder than a typical logistics update. Net income jumped 53.1% to $7.5 million for the quarter ended June 30, while revenue climbed 18.5% to $261.4 million. Look past that one quarter, though, and the picture gets more complicated, because full-year adjusted profitability actually fell. That gap between a blowout quarter and a softer year is what makes this name worth a closer look.
The fourth fiscal quarter was strong from top to bottom. Adjusted EBITDA rose 31.6% to $10.4 million, margin expanded 240 basis points to 15.5%, and adjusted net income climbed 34.5% to $7.4 million, all against organic revenue growth of 8%. Management credited the acceleration to US forwarding operations and international airfreight, including work supporting disaster relief after typhoon activity hit the Western Pacific earlier this year, plus airfreight demand tied to capital flows into global data center buildouts.
The balance sheet backs up the story. Radiant enters fiscal 2027 with zero net debt, $25.6 million in cash as of June 30, and a $200 million senior credit facility that was extended and restated in August, pushing maturity out to August 7, 2031, while its acquisition-focused accordion grew to $100 million from $75 million. On the domestic side, capacity has been exiting the truckload and intermodal markets, and spot rates and tender rejections moved higher late in the quarter. Radiant also launched a new independent agent program at Radiant Road & Rail during the quarter, extending its freight forwarding agent network into truck brokerage and intermodal, while Navegate is gaining traction, with one enterprise customer now managing more than 1,400 vendors on the platform.
The full-year numbers tell a different story than the quarter does. Revenue rose just 3.5% to $934.4 million from $902.7 million, a fraction of the fourth quarter's 18.5% pace, and full-year net income grew a modest 8.7% to $18.8 million. Full-year adjusted EBITDA actually fell 5.4% to $36.7 million from $38.8 million, and that figure included a $1.3 million First Brands adjustment. Strip that out and normalized adjusted EBITDA comes in at $35.4 million, an even steeper decline than the headline number suggests.
The operating backdrop stays complicated too. Ocean shipping routes remain disrupted by the closure of the Strait of Hormuz and continued Houthi activity affecting Suez Canal transits, keeping capacity tight on key trade lanes. US tariff policy is generating elevated IEEPA-related filing activity, and Canada put new retaliatory tariff measures into effect in early September, adding fresh complexity for shippers moving goods across that border. Management itself acknowledged that the domestic truck brokerage improvement seen late in the fourth quarter is not yet fully reflected in the reported results.

#million #quarter #revenue #fiscal

Choosing between Advance Auto Parts (NYSE:AAP) and Intuitive Machines (NASDAQ:LUNR) requires balancing the steady but challenged automotive retail sector against the high-stakes, high-growth arena of ******* e infrastructure.
Advance Auto Parts operates as a massive retailer for vehicle maintenance, while Intuitive Machines focuses on lunar landers and orbital services. These two businesses represent very different risk-to-reward profiles for 2026 portfolios.
Advance Auto Parts operates as an automotive aftermarket parts retailer, serving both everyday do-it-yourselfers and professional installers like garages or dealerships. In its latest annual report, filed for the fiscal year ended January 3, 2026, the company noted it operates over 4,000 stores across North America. As an established player among retail stocks, its strategy relies on balancing these two customer bases, with professional sales accounting for nearly 50% of its total revenue.
In FY 2025, revenue reached $8.6 billion, representing a revenue decline of roughly 5.4% compared to the previous year. Despite this decline, the company reported a net income of $44.0 million. This resulted in a thin net margin, a measure of how much profit a company keeps from its total sales, of about 0.5%.
As of its January 2026 balance sheet, the debt-to-equity ratio was 2.4x. This ratio measures total debt against shareholder equity, with a higher number suggesting more reliance on borrowing. The so-called current ratio, which tracks the ability to pay short-term debts with short-term ******* ets, was 1.7x. Free cash flow, defined as cash from operations minus capital expenditures, was negative $298.0 million for the year.

#parts #operates #total #ratio

Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Mission Lane is a credit card company that offers cash-back rewards cards as well as card options for people with less-than-perfect credit.
There are four Mission Lane cards, and each is designed for people with different credit profiles. But it's important to understand the details of each one and the costs they can carry before you apply. Here are 5 things to know about Mission Lane credit cards:
The four credit cards offered by Mission Lane differ in card type, rewards offered, qualifications, and more. Here's a closer look at how they compare:
Annual fee

#offers

On September 14, Dave & Buster's Entertainment (NASDAQ:PLAY) reported second-quarter fiscal 2026 results that read like two different companies at once. Revenue fell, and the company posted a net loss for the period ended August 4, yet comparable sales, which had been sliding for more than a year, kept getting less bad every month from June through the first five weeks of the third quarter. New CEO Darin Harper is betting that improvement compounds into something bigger.
The clearest evidence is the trend line itself. Comparable store sales fell 5.4% in the first quarter of fiscal 2026, then 2.9% in the second quarter, then just 1.6% in July after a 5% decline in June, and Harper said trends improved further over the first five weeks of the third quarter. Food and beverage sales are moving in the opposite direction entirely, up 7.6% in the quarter and positive for five straight quarters, helped by the Eat & Play Combo, a bundled meal and game credit offer sold through kiosks. Special event sales have now grown for seven consecutive quarters.
Behind that shift sits a rebuilt leadership bench. Dave & Buster's went more than a year without a chief marketing officer, and Harper has since added a CMO, a chief operations officer, a chief technology officer, and a chief legal officer since taking over. The company also leaned on new content, launching 10 games and attractions this year, including tie-ins with Mandalorian and Grogu, John Wick and Stranger Things, after research found more than 70% of guests said new games would bring them back more often. Changes to game pricing pushed play and dwell time up 16% to 20% or more. Six remodeled stores are already outperforming the rest of the chain, and management says the newest remodel template costs less to build than the last one. Net capital spending dropped to $127.6 million through the first half of the year from $155.4 million, and adjusted free cash flow swung to positive $19.5 million from negative $36.5 million, a $56 million improvement.
The headline figures were still rough. Total revenue slipped 2.4% to $544.1 million from $557.4 million a year earlier, and adjusted EBITDA dropped to $98.9 million, an 18.2% margin, from $129.8 million and a 23.3% margin. On a GAAP basis, the company posted a net loss of $12.5 million, or $0.36 per diluted share, versus net income of $11.4 million in the same quarter last year. About $15 million of the EBITDA decline came from items management calls non-normalized, including a $10 million noncash deferral adjustment that did not repeat this year, $3 million in extra preopening costs and $2 million in higher insurance expenses, but even stripped of those, the underlying decline was still roughly $16 million.

#quarter #sales

Billionaire Ray Dalio's Bridgewater ****** ociates and Cathie Wood's ARK Invest follow sharply different investment philosophies. Bridgewater generally runs a diversified, macro-driven portfolio that balances exposure across ****** ets, countries and economic environments. ARK concentrates on companies it believes can benefit from disruptive innovation.
Still, Insider Monkey's ****** ysis of their second-quarter 13F filings shows that the two firms shared exposure to several stocks. Among the largest common holdings were Eli Lilly (LLY) and Nvidia (NVDA).
Bridgewater held 87,023 Eli Lilly shares worth about $104.4 million at the end of the second quarter, after increasing its position by 16,211 shares. ARK held 77,254 shares valued at about $92.7 million, after adding 64,578 shares.
Bridgewater's Nvidia stake was much larger, comprising 3.87 million shares worth about $773.6 million. However, it reduced the position by 826,808 shares during the quarter. ARK moved in the other direction, adding 345,821 Nvidia shares to end the quarter with 1.38 million shares valued at about $276.4 million.
Let's focus on LLY.

#lilly

Broadcom (NASDAQ: AVGO) has been one of the quieter top-performing investments throughout the AI arms race. If you invested $5,000 at the start of the AI arms race in 2023, that sum is now worth more than $32,000. However, investors must look forward, not backward. Luckily, Broadcom's future is brighter than ever, and I think a $5,000 investment now could lead to a much larger sum later.
While it won't be able to repeat the incredible performance it gave investors over the past three and a half years, I think it's still worth buying now.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Broadcom does a lot of different things as a company, ranging from software to virtual desktops to networking hardware. However, the most exciting product development over the past few years has been its custom AI chips. Instead of going head-to-head with companies in the GPU ***** e, which excel at all types of workloads, Broadcom is partnering directly with AI hyperscalers to develop chips purpose-built for their workloads. These units can provide better performance at a lower price tag than their GPU counterparts, but only when the workloads are properly configured.
Broadcom has several big-name clients, including Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), Meta Platforms (NASDAQ: META), OpenAI, and Anthropic, to name a few. These companies have all chosen to partner with Broadcom over some other competitors in this ***** e, and the results have been simply incredible.

#NVIDIA #meta

Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below.
Warren Buffett once put General Motors CEO Mary Barra on the spot with a question. Would she run the company differently if she didn't have to report earnings every three months?
When Barra said no, Buffett offered advice she still calls (1) "phenomenal."
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
A record 45% of central banks plan to grow gold reserves — and many investors are following suit. Get your free gold IRA guide from Priority Gold

#finance #warren #mary

Hayden Gillim won his second King of the Baggers Championship after splitting wins with Bradley Smith at Circuit of the Americas. Gillim also won the **** le in 2023 riding for the Vance & Hines Harley-Davidson team, and after the team switched to Indian this season, he became the first rider to win the **** le for two different manufacturers.
Gillim arrived at COTA with a 23-point lead over teammate Troy Herfoss and a 54-point gap over Harley-Davidson x Dynojet rider Smith. Gillim took Race 1 ahead of Smith and teammate Rocco Landers, while Herfoss retired after a crash on his third lap.
That result set up Race 2 on Sunday, where all Gillim needed to do was manage the gap rather than win outright. Gillim passed Herfoss on the opening lap but ceded the lead to Smith on the fourth lap. Smith held on to win by 4.717 seconds while Gillim held off SDI Racing's Tyler O'Hara to finish second. Herfoss finished off the podium in fifth, behind Harley-Davidson's James Rispoli.
With only a maximum of 50 points remaining across the two-race New Jersey finale, Gillim's 54-point cushion over Smith was enough to secure his second King of the Baggers crown.
"We didn't get the bikes until late and got one test in before the season started, and we came out winning," said Gillim, who won 8 of 12 races heading into New Jersey. "To be able to finish it early is pretty special, especially against the guys that we're racing against."

#smith #harley #king #baggers

Here's what we know after Monday's press conference in New York to announce the new MMA promotion backed by Strikeforce founder and former Bellator president Scott ******* er:
— It will be called Ki MMA, which looks like K-1 on paper but is ******* ounced like "key," which led to at least one accidental pun in just the first half-hour or so of conversation among the executives.
— Its fights will take place in a modified boxing ring, with such an abundance of tightly ******* ed ropes that should help us finally figure out if it's possible to use this set up without fighters getting tangled or falling through.
— It will focus on tournament-based competition, beginning with a 32-man featherweight tournament in 2027, that will draw fighters from four different continents — North America, South America, Europe and Asia — leading to a world grand prix final, where the eventual champion will have to win two fights in one night.
What we didn't find out was who will be in this tournament or where we'll be able to watch it. Those are typically two pretty important factors in determining whether or not fight fans will get on board, but I guess we're taking things one step at a time.

#bellator

Two races into NASCAR's new Chase, the championship standings are already showing how quickly things can change.
Kyle Larson left Darlington 49 points behind Denny Hamlin. One win at Gateway later, he sits second, just nine points back.
Ryan Blaney experienced the opposite. He entered Gateway 16 points behind Hamlin before a brake failure ended his race in 35th. Now he trails by 33.
Next comes Bristol Motor Speedway, and there is no reset waiting on the other side.
Under NASCAR's previous playoff format, drivers raced through elimination rounds with points resets along the way. The 2026 Chase is different. After the initial reseeding, all 10 races count toward the same championship total.

#points #championship

The 2026 home campaign for the Salt Lake Bees (24-44/63-79) came to a close this week as they welcomed the Round Rock Express (Triple-A, Texas Rangers). Known as the "E-Train," the Lone Star side steamrolled their way to a dominant series victory, winning five of six. Outside of a 11-1 thrashing on Thursday, the Bees never held a lead in the other five contests. The Express (38-31/69-75) collected their first road series win in Salt Lake since 2021, when they swept the Bees in a six-game set.
Despite a quality start from Bees starter Ryan Costeiu, Round Rock earned a 5-1 series opening victory on Tuesday. The visitors scored in four different frames, while Niko Kavadas helped Salt Lake avoid a shutout with a fifth-inning solo blast. Wednesday was more of the same, as the Express tallied a 6-1 victory. MLB rehabber Josh Jung punctuated the win with a solo blast in the eighth, as the Bees were held to just a trio of hits for the second straight game.
As mentioned above, the Salt Lake bats came alive on Thursday with an 11-1 rout. The team tied their season-high with four homers, spotlighted by Kavadas' second multi-homer night of the campaign. The infielder's surge was part of a four-hit night, his first at any level since 2022. On the mound, Joel Hurtado turned in 6.2 innings of one-run ball, finally collecting his first Triple-A win in his eighth try. After falling behind 5-0 on Friday, the Bees nearly completed a comeback, coming up just short in a 5-4 defeat. Salt Lake got the winning run on base in the ninth, but ultimately fell short.
The final Saturday and Sunday at home in 2026 were near carbon copies of each other. Big first innings for Round Rock put them in the driver's seat, leading 6-0 and 4-0, respectively. Saturday's output was more than enough for the visitors as they added seven more runs over the course of the game to shutout the Bees 13-0. On Sunday's home finale, Salt Lake battled and answered every time the Express scored. They closed the gap to 6-4 before Round Rock gained some length with Aaron Zavala's two-run blast in the sixth, the only longball of the evening. The Bees did not go down without a fight, bringing the tying run to the plate in the ninth. A flyball was tracked down for the 27th and final out of the finale, completing the Express' 9-6 victory.
The 74th and final home game saw 7,853 fans come through the turnstiles of The Ballpark at America First Square — the largest crowd in ballpark history. Salt Lake finished 35-39 at home this season, winning or splitting nine of their 13 total home series. The Bees were victorious in at least one game against every opponent who came to South Jordan, avoiding a sweep for the second straight season as the hosts.

#lake #express

Across our area, local children are hopping on bikes to develop a lifelong passion.
The goal of Independence Youth Cycling is to uplift members of their various teams.
When they set out on the trail with their peers, they're always in for a great ride.
"Our nonprofit supports teams that operate in different leagues and series across Pennsylvania and New Jersey. 65 or more coaches that support our organization...Our teams would not be here if it wasn't for the amazing green ***** es and trail systems that we have in Philadelphia and Montgomery County," said President and Founder of Independence Youth Cycling, John Raisch.
"It's been an amazing ride and we just want to see it continue into the future and be a strong, impactful organization," he continued.

#ride #pennsylvania

The Buffalo Bills got the better of the Houston Texans in their 2026 NFL regular season opener by taking a 36-31 win.
The contest saw the Bills exercise demons of the past in Houston. finally winning a game at Reliant Stadium for the first time in nearly two decades. It came in a whirlwind, comeback effort too.
Onlookers can learn plenty from such a game.
With that, here are Bills Wire's three things we learned from Week 1:
The Bills came from behind not just once but many times in this one. This Buffalo vs. Houston outing had eight different lead changes, a very high number. That's a sign of team that will battle for their head coach in Joe Brady, who earned it first-career win on Sunday.

#bills #came #reliant #onlookers

Mets news: Ex-GM drops 'disappointed' admission on NY not re-signing Pete Alonso appeared first on ClutchPoints. Add ClutchPoints as a Preferred Source by clicking here.
The New York Mets have the difficult task of facing the man who set their all-time home run record a little more than a year ago. He also happens to be responsible for one of the most famous dingers in recent playoff history. That is not the type of player fans want to see in a different uniform. Beloved first baseman Pete Alonso will return to Citi Field for the first time since inking a five-year, $155 million contract with the Baltimore Orioles last December, and with that big reunion comes endless evaluation and nitpicking.
Former Mets executive Sandy Alderson was running the front office when the organization selected the Polar Bear in the 2016 MLB Draft, so it is no surprise to hear how he feels about New York failing to re-sign Alonso.
"I was disappointed," Alderson told Brian Kenny on MLB Now, one day after being inducted into the Athletics Hall of Fame. "Pete Alonso was drafted by Tommy Tanous, the scouting director at that time, in the second round. Basically a home-run hitter who got on base. And that's what he's been since he came to the big leagues. Let's say his defense is not…. superb. Poor defense doesn't outweigh the kind of homegrown, home-run, impact talent that Pete Alonso can provide.
Watch sports LIVE with fuboTV (free trial)

#alonso #pete #first

On September 10, Shoe Station Group (NASDAQ:SHOE) held its first earnings call under its new name, and the numbers told a story of a company still finding its footing. Second quarter net sales fell 7.2% to $284.3 million from $306.4 million a year earlier, with comparable sales down 7.1%. But buried in the report was a sharper signal: August comparable sales improved to a 2.7% decline, a real jump from the second quarter's pace, and management is pointing to store-by-store product changes as the reason why.
Shoe Station's turnaround argument rests on giving up the idea that every store should look the same. Interim CEO Clifton Sifford said the company had been running nearly identical ***** ortments across its stores even though its two banners serve very different customers, and that approach stopped working. The shift already shows up in the numbers. Once the company localized its athletic ***** ortments ahead of back-to-school, adult athletic sales moved from a low single-digit decline in the second quarter to a low single-digit increase in August.
Running shoes comped positive in both men's and women's categories, and men's work boots, a replenishment category with loyal repeat buyers, grew 2%. Management believes this fall's boot lineup is the best it has fielded in years, heading into what Sifford expects to be a bigger nonathletic fashion cycle. E-commerce sales grew 18.8% even as store traffic fell, and in-store conversion actually improved, evidence that customers who show up are buying; they just are not showing up in the same numbers yet. The company also ended the quarter debt-free with $131.6 million in cash, up $39.7 million from a year ago, giving it room to fund the localized rollout without straining the balance sheet.
The flip side is that the entire second quarter was ugly across the board. Shoe Carnival branded stores, still 63% of revenue, saw sales fall 6.5%, while the newly converted Shoe Station banner dropped 8.4%. Gross profit margin fell 690 basis points to 31.9%, a mix of a promotional footwear market and management's decision to accelerate liquidation of aged inventory, trading margin for cash. That combination cut net income to $6.3 million, or $0.23 per diluted share, down from $19.2 million and $0.70 a year earlier.
Management is not projecting relief anytime soon. Sifford said plainly, "We are not ***** uming the environment improves," and CFO Kerry Jackson noted that gross margins in fiscal August were still running below last year's levels at a pace comparable to the second quarter. Full-year gross margin guidance of 32.5% to 32.7% implies 390 to 410 basis points of compression for the year. Store impairment charges reached $6.7 million on 11 stores year to date, and management has already conceded that the core problem is not price, since conversion rates rose while total customer visits kept falling. That points to a marketing and trust problem rather than a demand problem, and fixing it will take more tha